Caribou Biosciences, Inc - CRBU Revenue Dynamics YoY (Last Twelve Months)

Graphic logo of Caribou Biosciences, Inc (CRBU)

Caribou Biosciences (CRBU) leverages unique CRISPR platforms to develop cancer therapies, ensuring patent resilience and capital inflows from pharmaceutical behemoths. The compound annual growth rate of sales (trailing 12 months) reflects implementation dynamics, with the latest figure standing at 1.50. Its status as a scientific elite, founded by a Nobel laureate, guarantees market confidence as the company implements high-precision allogeneic treatments for long-term cancer control.

Caribou Biosciences (CRBU): Sales Growth YoY (TTM) from 02/11/2024 to 11/19/2026

Caribou Biosciences, Inc (CRBU) - metric breakdowns and financial figures

- stock price and consensus target price:
Fundamental company valuation:Caribou Biosciences
Flagship merchandise of Caribou Bio

This indicator measures revenue dynamics over the last twelve months relative to the previous year, allowing for an assessment of the business's actual expansion speed via market consensus. Since Caribou Biosciences (CRBU) is in the clinical trial stage without commercial products, the year-over-year sales trajectory (TTM) reflects only partnership grants, rendering its capital dependent on R&D funding.